Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7127074 | 0.75 | CYP2C19 (0.34) | CYP2C19HSD17B10TDP1LMNA | |
| SCHEMBL3224348 | 0.74 | CYP2C19 (0.58) | CYP2C19TDP1LMNACYP1A2CYP3A4 | |
| SCHEMBL12814071 | 0.74 | CETP (0.42) | HSD17B10TDP1 | |
| SCHEMBL11445178 | 0.74 | HSD17B10 (0.30) | HSD17B10TDP1 | |
| SCHEMBL11760382 | 0.70 | MAOB (0.32) | — | |
| SCHEMBL21546399 | 0.69 | — | — | |
| SCHEMBL5902373 | 0.67 | — | — | |
| SCHEMBL11650478 | 0.67 | HSD17B10 (0.39) | HSD17B10TDP1 | |
| SCHEMBL8382997 | 0.67 | CYP2C19 (0.61) | CYP2C19TDP1 | |
| SCHEMBL7526128 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4113968-A | FROM A 1-HALO-3-ALKENE-2-OL | KURARAY CO., LTD. (JP) | 1978-09-12 | — | — | US | claimed |
| EP-1238704-B1 | Catalyst comprising a cyclic imide compound and process for producing organic compounds using the catalyst | DAICEL CHEM (JP) | 2015-01-21 | — | — | EP | disclosed |
| EP-1433527-B1 | CATALYSTS COMPRISED OF N-SUBSTITUTED CYCLIC IMIDES AND PROCESSES FOR PREPARING ORGANIC COMPOUNDS WITH THE CATALYSTS | DAICEL CHEM (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-7759515-B2 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compounds using the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| US-7741514-B2 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| US-7368615-B2 | Catalyst comprising a cyclic imide compound and process for producing organic compounds using the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-7183423-B1 | Process for the preparation of organic compounds with imide catalysts | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20060281629-A1 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst | ISHII YASUTAKA | 2006-12-14 | — | — | US | disclosed |
| US-20060229196-A1 | Catalyst comprising n-substituted cyclic imide compound and process for producing organic compounds using the catalyst | ISHII YASUTAKA | 2006-10-12 | — | — | US | disclosed |
| US-7115541-B2 | Catalyst comprising n-substituted cyclic imides and processes for preparing organic compounds with the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2006-10-03 | — | — | US | disclosed |
| US-4198343-A | Method of preparing dihalogen vinyl cyclopropanecarboxylic acid esters | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) | 1980-04-15 | — | — | US | disclosed |
| US-4198342-A | Method of preparing dihalogen vinyl cyclopropanecarboxylic acid esters | DYNAMIT NOBEL ATKIENGESELLSCHAFT (DE) | 1980-04-15 | — | — | US | disclosed |
| US-4190730-A | CATALYTIC THERMAL ISOMERIZATION | KURARAY CO., LTD. (JP) | 1980-02-26 | — | — | US | disclosed |
| US-4180446-A | Method of preparing dihalogen vinyl cyclopropanecarboxylic acid esters | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) | 1979-12-25 | — | — | US | disclosed |
| EP-0003666-A1 | Oxabicyclo 3.1.0 hexanes useful in the production of cyclopropanecarboxylate insecticides and intermediate compounds | FMC Corporation (US) | 1979-08-22 | — | — | EP | disclosed |
| US-4117247-A | THERMAL ISOMERIZATION | KURARAY CO., LTD. (JP) | 1978-09-26 | — | — | US | disclosed |
| US-4113968-A | FROM A 1-HALO-3-ALKENE-2-OL | KURARAY CO., LTD. (JP) | 1978-09-12 | — | — | US | disclosed |
| US-4098657-A | Electrolyte dehydrohalogenation of α-haloalcohols | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-07-04 | — | — | US | disclosed |
| US-4083855-A | Method for producing a γ-lactone | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1978-04-11 | — | — | US | disclosed |
| US-4022672-A | Electrochemical synthesis of insecticide intermediates | FMC CORPORATION (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229196-A1 | Catalyst comprising n-substituted cyclic imide compound and process for producing organic compounds using the catalyst | NOS2, NOS1, NOS3 | CYP2C19 205/4885HSD17B10 1823/4885TDP1 3824/4885 |
| US-20060281629-A1 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst | NOS2, NOS1, NOS3 | CYP2C19 219/4885HSD17B10 1825/4885TDP1 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.